Proteon Therapeutics appoints Paul J. Hastings as chairman
Mr. Hastings has over three decades of operations experience in the biopharmaceutical industry, including roles as Chief Executive Officer at multiple public companies.
He is President and Chief Executive Officer of OncoMed Pharmaceuticals and Chairman of its Board since 2013.
Mr. Hastings is the President and Chief Executive Officer of OncoMed Pharmaceuticals, and Chairman of the Board of Directors. He served as President and Chief Executive Officer of QLT and Axys Pharmaceuticals which was acquired by Celera Corporation.
Mr. Hastings also served as the President of Chiron BioPharmaceuticals, President and Chief Executive Officer of LXR Biotechnology, and held a series of management positions at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics.
Mr. Hastings served as Vice President, Marketing and Sales and General Manager, Europe for Synergen and held a series of marketing and sales management positions with Hoffmann-La Roche.
He was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2009), and served on the boards of Relypsa (sold to Galenica in 2016), ViaCell (sold to Perkin-Elmer in 2008), and Cerimon Pharmaceuticals.
Mr. Hastings is currently on the boards of OncoMed Pharmaceuticals and Pacira Pharmaceuticals, serves as Vice Chairman of Biotechnology Innovation Organization (BIO), and is also on the board of directors of the California Life Sciences Association.
Mr. Hastings received a B.S. in Pharmacy from the University of Rhode Island.